文献速递肝病消化道肿瘤与早癌

肝细胞癌患者活体供肝肝移植较尸体供肝肝移植生存率提高

Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.
PubMed 文献 · J Hepatol · 2019-01-08

该研究纳入2000至2015年等待肝移植的肝细胞癌患者,比较有潜在活体供者(pLDLT组219例)与无活体供者(pDDLT组632例)的意向性治疗生存。pLDLT组1、3、5年生存率分别为86%、72%、68%,高于pDDLT组的82%、63%、57%(p=0.02);有潜在活体供者是死亡的保护因素(HR 0.67;95%CI 0.53-0.86)。

要点

  • 有潜在活体供者的肝细胞癌患者意向性治疗生存率高于无活体供者。
  • 有潜在活体供者是死亡的保护因素(HR 0.67;95%CI 0.53-0.86)。
  • 等待9-12个月(HR 1.53)和≥12个月(HR 1.69)是死亡的预测因素。

核心结论

  • 在意向性治疗分析中,肝细胞癌患者 listing 时有潜在活体供者与死亡风险显著降低相关。
  • 该获益与较低的脱落率和较短的等待时间相关。

研究设计与样本

  • 纳入2000至2015年所有等待肝移植的肝细胞癌患者。
  • pLDLT组为 listing 时识别出潜在活体供者的受者,共219例;pDDLT组为无活体供者的患者,共632例。
  • 采用Kaplan-Meier法评估生存,多变量Cox回归识别死亡预测因素。

主要发现

  • pLDLT组57例(26%)超出UCSF标准,pDDLT组119例(19%)超出(p=0.02)。
  • pLDLT组等待时间短于pDDLT组(4.8[2.9-8.5]个月 vs. 6.2[3.0-12.0]个月,p=0.02)。
  • pLDLT组脱落率为32/219(14.6%),pDDLT组为174/632(27.5%),p<0.001。
  • pLDLT组1、3、5年意向性治疗生存率分别为86%、72%、68%,pDDLT组分别为82%、63%、57%,p=0.02。
  • 有潜在活体供者是死亡的保护因素(HR 0.67;95%CI 0.53-0.86);等待9-12个月(HR 1.53;95%CI 1.02-2.31)和≥12个月(HR 1.69;95%CI 1.23-2.32)是死亡预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are conflicting reports on the outcomes after live donor liver transplantation in patients with hepatocellular carcinoma (HCC). We aimed to compare the survival of patients with HCC, with a potential live donor (pLDLT) at listing vs. no potential donor (pDDLT), on an intention-to-treat basis. METHODS: All patients with HCC listed for liver transplantation between 2000-2015 were included. The pLDLT group was comprised of recipients with a potential live donor identified at listing. Patients without a live donor were included in the pDDLT group. Survival was assessed by the Kaplan-Meier method. Multivariable Cox regression was applied to identify potential predictors of mortality. RESULTS: A total of 219 patients were included in the pLDLT group and 632 patients in the pDDLT group. In the pLDLT group, 57 patients (26%) were beyond the UCSF criteria whereas 119 patients (19%) in the pDDLT group were beyond (p = 0.02). Time on the waiting list was shorter for the pLDLT than the pDDLT group (4.8 [2.9-8.5] months vs. 6.2 [3.0-12.0] months, respectively, p = 0.02). The dropout rate was 32/219 (14.6%) in the pLDLT and 174/632 (27.5%) in the pDDLT group, p <0.001. The 1-, 3- and 5-year intention-to-treat survival rates were 86%, 72% and 68% in the pLDLT vs. 82%, 63% and 57% in the pDDLT group, p = 0.02. Having a potential live donor was a protective factor for death (hazard ratio [HR] 0.67; 95% CI 0.53-0.86). Waiting times of 9-12 months (HR 1.53; 95% CI 1.02-2.31) and ≥12 months (HR 1.69; 95% CI 1.23-2.32) were predictors of death. CONCLUSION: Having a potential live donor at listing was associated with a significant decrease in the risk of death in patients with HCC in this intention-to-treat analysis. This benefit is related to a lower dropout rate and a shorter waiting period. LAY SUMMARY: Liver transplantation (LT) offers the best chance of survival for patients with hepatocellular carcinoma and can be performed using grafts from deceased donors or live donors. In this work, we aimed to assess the differences in survival after live donor LT when compared to deceased donor LT. We studied 219 patients listed for live donor LT and 632 patients listed for deceased donor LT. Patients who had a potential live donor at the time of listing had a higher survival rate. Therefore, being listed for a live donor LT was a protective factor against death.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Goldaracena N, Gorgen A, Doyle A, et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J Hepatol. 2019. PMID: 30630009. doi:10.1016/j.jhep.2018.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。